Truist Securities Reiterates Buy on IGM Biosciences, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene has reiterated a 'Buy' rating on IGM Biosciences (NASDAQ:IGMS) and maintained a price target of $25.
September 06, 2023 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IGM Biosciences has been reiterated with a 'Buy' rating by Truist Securities, with a maintained price target of $25.
The 'Buy' rating from Truist Securities indicates a positive outlook for IGM Biosciences. The maintained price target of $25 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100